Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical has announced that its subsidiary, Jinzhou Avanc Pharmaceutical, has received acceptance from the National Medical Products Administration for the registration application of Fovinaciclib citrate capsules. This new drug is a CDK4/6 inhibitor intended for use in treating HR-positive and HER2-negative locally advanced or metastatic breast cancer, marking a significant step in the company’s efforts to enhance its oncology drug portfolio.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading healthcare company based in China, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is known for its commitment to innovative drug research and development, particularly in the field of oncology and other therapeutic areas.
YTD Price Performance: -10.23%
Average Trading Volume: 1,184
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.96B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.
